Get the Stockscreener App
18.43
1.76%
-0.345
Relay Therapeutics Inc stock is traded at $18.43, with a volume of 1.46M.
It is down -1.76% in the last 24 hours and down -2.07% over the past month.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
See More
Previous Close:
$18.77
Open:
$18.64
24h Volume:
1.46M
Relative Volume:
0.39
Market Cap:
$4.04B
Revenue:
$10.68M
Net Income/Loss:
$-272.71M
P/E Ratio:
-11.77
EPS:
-1.565
Net Cash Flow:
$-213.38M
1W Performance:
-6.68%
1M Performance:
-2.07%
6M Performance:
+79.73%
1Y Performance:
+413.65%
1-Day Range:
$18.03
$18.64
1-Week Range:
$18.03
$20.77
52-Week Range:
$3.57
$21.27
Relay Therapeutics Inc Stock (RLAY) Company Profile
Name
Relay Therapeutics Inc
Sector
Industry
Phone
617-370-8837
Address
60 HAMPSHIRE STREET, CAMBRIDGE
Compare RLAY vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
18.43 | 4.32B | 10.68M | -272.71M | -213.38M | -1.565 |
VRTX
Vertex Pharmaceuticals Inc
|
541.97 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
797.35 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,022.07 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
141.01 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.48 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Dec-12-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Apr-17-25 | Initiated | Wells Fargo | Equal Weight |
| Sep-10-24 | Resumed | Goldman | Buy |
| Sep-10-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-10-24 | Downgrade | Oppenheimer | Outperform → Perform |
| May-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-20-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-19-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-23 | Initiated | Raymond James | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Sep-30-22 | Initiated | Barclays | Equal Weight |
| Sep-02-22 | Initiated | Stifel | Buy |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Jul-21-21 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-08-20 | Initiated | JMP Securities | Mkt Outperform |
| Nov-05-20 | Initiated | H.C. Wainwright | Buy |
| Aug-10-20 | Initiated | Cowen | Outperform |
| Aug-10-20 | Initiated | Goldman | Buy |
| Aug-10-20 | Initiated | Guggenheim | Buy |
| Aug-10-20 | Initiated | JP Morgan | Neutral |
View All
Relay Therapeutics Inc Stock (RLAY) Latest News
What is HC Wainwright's Estimate for RLAY FY2027 Earnings? - MarketBeat
RLAY Maintained by HC Wainwright & Co. -- Price Target Raised to $29 - GuruFocus
Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright raises Relay Therapeutics price target to $29 By Investing.com - Investing.com Canada
Relay Therapeutics, Inc. $RLAY Shares Bought by Bank of America Corp DE - MarketBeat
Relay Therapeutics (RLAY) Reported Q2 Results, Is The Premium P B Multiple Justified? - Yahoo Finance
Relay Therapeutics (RLAY) Stock May Be Fully Valued After A 7x Run - simplywall.st
Timothy G. Youngquist 2020 Irrevocable Trust Boosts Stake in Relay Therapeutics, Inc. $RLAY - MarketBeat
Handelsbanken Fonder AB Buys New Shares in Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics Insider Sold Shares Worth $979,886, According to a Recent SEC Filing - marketscreener.com
Relay Therapeutics (RLAY) CEO sells 48K shares in plan trade - Stock Titan
Relay Therapeutics (RLAY) CFO sells shares via preset trading plan - Stock Titan
Relay (RLAY) Earnings Metrics: EPS Does Not Reach the Reported Estimate in Latest Trading - Vinanet
Relay Therapeutics stock hits 52-week high at 20.83 USD - Investing.com
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci - The Globe and Mail
Alphabet Inc. Makes New Investment in Relay Therapeutics, Inc. $RLAY - MarketBeat
RLAY Stock Declines Pre-Market After $175M Offering — Despite Fresh Bullish Calls On Relay's Zovegalisib - Stocktwits
Why Is RLAY Stock Rising Today? - Stocktwits
Relay Therapeutics (NASDAQ:RLAY) Sets New 52-Week High Following Analyst Upgrade - MarketBeat
Persistent Asset Partners Ltd Makes New $1.32 Million Investment in Relay Therapeutics, Inc. $RLAY - MarketBeat
Elmind Capital, LP's Relay Therapeutics Inc(RLAY) Holding History - GuruFocus
Relay Therapeutics (NASDAQ:RLAY) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
PERCEPTIVE ADVISORS LLC Expands Relay Therapeutics Inc (RLAY) St - GuruFocus
Relay Therapeutics (RLAY): Commodore Capital group discloses 12M-share, 5.5% position - Stock Titan
J.P. Morgan Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Announces Target Price $31 - Moomoo
RLAY Maintained by JP Morgan -- Price Target Raised to $31.00 - GuruFocus
Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Relay Therapeutics Stock Is Up Nearly 500% Over the Past Year - Barchart.com
Relay Therapeutics, Inc. $RLAY Shares Bought by California State Teachers Retirement System - MarketBeat
These Analysts Think Relay Therapeutics, Inc.'s (NASDAQ:RLAY) Sales Are Under Threat - simplywall.st
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Cutting Their Estimates: Here's What You Need To Know - webull.com
Relay Therapeutics (RLAY) Holds at $19.99 as Biotech Consolidates Between Key Support and ResistanceWyckoff Distribution - vinanet.vn
Relay Therapeutics (RLAY): Perceptive Advisors discloses 6.4% ownership stake - Stock Titan
RLAY Maintained by Citizens -- Price Target Raised to $26 - GuruFocus
Citizens Jmp Increases Relay Therapeutics (NASDAQ:RLAY) Price Target to $26.00 - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) Just Reported And Analysts Have Been Cutting Their Estimates - Moomoo
Citizens raises Relay Therapeutics stock price target on progress By Investing.com - in.investing.com
Citizens raises Relay Therapeutics stock price target on progress - Investing.com
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
RLAY Maintained by Barclays -- Price Target Raised to $30.00 - GuruFocus
FMR LLC (RLAY) discloses 21.27M-share, 10% holding in Relay Therapeutics - Stock Titan
Relay Therapeutics Inc (RLAY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Relay Therapeutics, Inc. (RLAY): Investor Outlook On A Biotech With 33% Potential Upside - DirectorsTalk Interviews
Is Relay Therapeutics Inc (RLAY) Overvalued After Q2 Earnings Mi - GuruFocus
Guggenheim reiterates Buy on Relay Therapeutics stock, $26 target By Investing.com - Investing.com Canada
Relay Therapeutics president and CEO Sanjiv Patel sells $943,736 in stock - Investing.com Nigeria
Relay Therapeutics, Inc. Stock 12‑Month Price Target Raised to $26.31, Implies 33% Upside - TradingView
Relay Therapeutics Q2 Results: Sales drop 48% YoY, miss estimates - scanx.trade
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Earnings Flash (RLAY) Relay Therapeutics Posts Q2 Loss $0.41 per Share, vs. FactSet Est of $0.39 Loss - marketscreener.com
Relay Therapeutics Inc Stock (RLAY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Relay Therapeutics Inc Stock (RLAY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SVF Pauling (Cayman) Ltd | 10% Owner |
Aug 25 '26 |
Sale |
19.40 |
6,000,000 |
116,400,000 |
21,904,963 |
0.74%
1.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):